Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.972 SEK | +3.40% | +4.29% | -78.68% |
May. 29 | Elicera Therapeutics Set to Begin First Clinical CAR T-Cell study CARMA | CI |
May. 27 | Elicera Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 3M 285K | Sales 2025 * | - | Capitalization | 34.11M 3.24M |
---|---|---|---|---|---|
Net income 2024 * | -29M -2.76M | Net income 2025 * | -33M -3.14M | EV / Sales 2024 * | 8.37 x |
Net cash position 2024 * | 9M 855K | Net cash position 2025 * | 47M 4.47M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.66
x | P/E ratio 2025 * |
-0.59
x | Employees | 2 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 21.66% |
1 day | +3.40% | ||
1 week | +4.29% | ||
1 month | +3.40% | ||
3 months | -42.65% | ||
6 months | -80.44% | ||
Current year | -78.68% |
Managers | Title | Age | Since |
---|---|---|---|
Magnus Essand
FOU | Founder | 60 | 13-12-31 |
Di Yu
FOU | Founder | 39 | 13-12-31 |
Jamal El-Mosleh
CEO | Chief Executive Officer | 43 | 13-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 19-12-31 | |
Director/Board Member | 73 | 19-12-31 | |
Chairman | 68 | 19-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 0.972 | +3.40% | 343,826 |
24-05-30 | 0.94 | -0.42% | 233,870 |
24-05-29 | 0.944 | -1.05% | 115,801 |
24-05-28 | 0.954 | +1.49% | 213,415 |
24-05-27 | 0.94 | +0.86% | 1,019,042 |
Delayed Quote Nasdaq Stockholm, May 31, 2024 at 11:20 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-78.68% | 3.24M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- ELIC Stock